Madan, V
Shyamsunder, P
Han, L
Mayakonda, A
Nagata, Y
Sundaresan, J
Kanojia, D
Yoshida, K
Ganesan, S
Hattori, N
Fulton, N
Tan, K-T
Alpermann, T
Kuo, M-C
Rostami, S
Matthews, J
Sanada, M
Liu, L-Z
Shiraishi, Y
Miyano, S
Chendamarai, E
Hou, H-A
Malnassy, G
Ma, T
Garg, M
Ding, L-W
Sun, Q-Y
Chien, W
Ikezoe, T
Lill, M
Biondi, A
Larson, R A
Powell, B L
Lübbert, M
Chng, W J
Tien, H-F
Heuser, M
Ganser, A
Koren-Michowitz, M
Kornblau, S M
Kantarjian, H M
Nowak, D
Hofmann, W-K
Yang, H
Stock, W
Ghavamzadeh, A
Alimoghaddam, K
Haferlach, T
Ogawa, S
Shih, L-Y
Mathews, V
Koeffler, H P
Article History
Received: 1 December 2015
Revised: 12 February 2016
Accepted: 15 March 2016
First Online: 11 April 2016
Competing interests
: Dr Haferlach declares part ownership of MLL Munich Leukemia Laboratory. Dr Alpermann is an employee of MLL Munich Leukemia Laboratory. The other authors declare no conflict of interest.